title: Oral phosphorus supplementation secondarily increases circulating fibroblast growth factor 23 levels at least partially via stimulation of parathyroid hormone secretion.
abstract: Oral phosphorus supplementation stimulates fibroblast growth factor 23 (FGF23) secretion; however, the underlying mechanism remains unclear. The aim of this study was to investigate the involvement of parathyroid hormone (PTH) in increased plasma FGF23 levels after oral phosphorus supplementation in rats. Rats received single dose of phosphate with concomitant subcutaneous injection of saline or human PTH (1-34) after treatment with cinacalcet or its vehicle. Cinacalcet is a drug that acts as an allosteric activator of the calcium-sensing receptor and reduces PTH secretion. Plasma phosphorus and PTH levels significantly increased 1 h after oral phosphorus administration and returned to basal levels within 3 h, while plasma FGF23 levels did not change up to 2 h post-treatment, but rather significantly increased at 3 h after administration and maintained higher levels for at least 6 h compared with the 0 time point. Plasma PTH and FGF23 levels were significantly lower in the cinacalcet-treated rats than in the vehicle-treated rats. Plasma phosphorus levels were significantly higher in the cinacalcet-treated rats than in the vehicle-treated rats at 2, 3, 4, and 6 h after oral phosphorus administration. Furthermore, rats treated with cinacalcet+human PTH (1-34) showed transiently but significantly higher plasma FGF23 levels at 3 h after oral phosphorus administration compared with cinacalcet-treated rats. These results suggest that oral phosphorus supplementation secondarily increases circulating FGF23 levels at least partially by stimulation of PTH secretion.
authors: Food Science Research Laboratories, Division of Research and Development, Meiji Co., Ltd.
authors: Satoshi
authors: S
authors: Takasugi
authors: Miho
authors: M
authors: Akutsu
authors: Masashi
authors: M
authors: Nagata
mesh_terms: D000818:Animals; D000069449:Cinacalcet; D019587:Dietary Supplements; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D009281:Naphthalenes / Q000494:pharmacology; D010281:Parathyroid Hormone / Q000378:metabolism*; D010710:Phosphates / Q000097:blood / Q000494:pharmacology; D010758:Phosphorus / Q000097:blood / Q000494:pharmacology*; D016226:Phosphorus, Dietary / Q000097:blood / Q000494:pharmacology*; D017208:Rats, Wistar; D044169:Receptors, Calcium-Sensing / Q000378:metabolism
chemical_list: C000717427:FGF23 protein, human; D009281:Naphthalenes; D010281:Parathyroid Hormone; D010710:Phosphates; D016226:Phosphorus, Dietary; D044169:Receptors, Calcium-Sensing; D010758:Phosphorus; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D000069449:Cinacalcet